New Zealand markets closed

Talis Biomedical Corporation (TLIS)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
9.30+0.02 (+0.22%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 16.94M
Enterprise value -40.12M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)41.03
Price/book (mrq)0.25
Enterprise value/revenue -26.65
Enterprise value/EBITDA 0.86

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 337.78%
S&P500 52-week change 326.27%
52-week high 39.60
52-week low 34.35
50-day moving average 38.74
200-day moving average 37.39

Share statistics

Avg vol (3-month) 39.32k
Avg vol (10-day) 38.86k
Shares outstanding 51.82M
Implied shares outstanding 61.82M
Float 81.01M
% held by insiders 18.31%
% held by institutions 143.42%
Shares short (30 Apr 2024) 413.38k
Short ratio (30 Apr 2024) 41.45
Short % of float (30 Apr 2024) 41.15%
Short % of shares outstanding (30 Apr 2024) 40.73%
Shares short (prior month 28 Mar 2024) 413.3k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 306 Jul 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-19,338.36%

Management effectiveness

Return on assets (ttm)-34.31%
Return on equity (ttm)-68.60%

Income statement

Revenue (ttm)989k
Revenue per share (ttm)0.54
Quarterly revenue growth (yoy)-94.00%
Gross profit (ttm)N/A
EBITDA -58.31M
Net income avi to common (ttm)-57.21M
Diluted EPS (ttm)-34.12
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)70.34M
Total cash per share (mrq)38.6
Total debt (mrq)19.24M
Total debt/equity (mrq)33.94%
Current ratio (mrq)7.51
Book value per share (mrq)31.11

Cash flow statement

Operating cash flow (ttm)-43.2M
Levered free cash flow (ttm)-32.09M